View ValuationMirion Technologies 향후 성장Future 기준 점검 4/6Mirion Technologies (는) 각각 연간 64.4% 및 10.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 57.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.6% 로 예상됩니다.핵심 정보64.4%이익 성장률57.39%EPS 성장률Electronic 이익 성장0%매출 성장률10.4%향후 자기자본이익률9.57%애널리스트 커버리지Good마지막 업데이트16 Jun 2026최근 향후 성장 업데이트공시 • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.공시 • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.공시 • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.모든 업데이트 보기Recent updatesNew Risk • Jun 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Shares are highly illiquid. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Significant insider selling over the past 3 months (Mex$2.8m sold).Board Change • Jun 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.공시 • Apr 16Mirion Technologies, Inc. to Report Q1, 2026 Results on Apr 28, 2026Mirion Technologies, Inc. announced that they will report Q1, 2026 results After-Market on Apr 28, 2026공시 • Apr 02Mirion Technologies, Inc., Annual General Meeting, May 13, 2026Mirion Technologies, Inc., Annual General Meeting, May 13, 2026.공시 • Feb 11+ 1 more updateMirion Technologies, Inc. Announces Management AppointmentsMirion Technologies, Inc. announced three new leadership appointments supporting the company’s continued focus on safety, innovation, operational excellence and long-term growth. Mirion has promoted Tighe Smith to the newly created role of Chief Nuclear Officer. Reporting to Thomas Logan, Mirion Chairman and Chief Executive Officer, Smith will lead the company’s global nuclear strategy across the existing operating fleet as well as the rapidly expanding advanced and small modular reactor (SMR) markets. Smith brings more than 20 years of experience spanning nuclear engineering, digital safety systems, international commercial leadership, and industry policy engagement. Smith most recently held the Chief Nuclear Officer role at Paragon Energy Solutions, now part of Mirion, and will retain these duties in addition to his expanded role. He is also an active contributor to the broader nuclear community, serving as a Trustee of the American Nuclear Society and as Convenor of IEC SC45A Working Group 9, helping advance international standards for nuclear instrumentation and control. He holds a Bachelor of Science in Nuclear Engineering and an MBA from the University of Tennessee, Knoxville. In addition to Nuclear Power, Nuclear Medicine serves as a robust, continually evolving market for Mirion. To further support Mirion’s strategic growth in this key market, Shelia Webb becomes President of Nuclear Medicine. In this role, Webb will lead the overall Nuclear Medicine business unit, focusing on strategic development and furthering the integration of the ec Software and Capintec brands to support advanced cancer care. Webb most recently served as Mirion Chief Digital Officer, playing a pivotal role in building a digital ecosystem that connects operating groups and enhances Mirion capabilities, efficiency and value. Following Mirion’s acquisition of ecSoftware in 2023, Webb assumed responsibility of business unit leader for ec Software and has been instrumental in integrating the company into the broader Capintec portfolio. Mirion also announced the appointment of Shahmeer Mirza as the company’s inaugural Chief Artificial Intelligence & Digital Officer, a new role intended to accelerate Mirion’s commitment to operational excellence and scalable growth through responsible, transformative AI strategies. In this role, Mirza assumes responsibility for Mirion’s Digital strategy as Webb transitions to the role of President, Nuclear Medicine. As Chief AI and Digital Officer, Mirza will lead the continuation of Mirion’s digital transformation roadmap leveraging technologies like AI to innovate, improve processes, and create new revenue streams. Reporting directly to Logan, Mirza will shape and execute the company’s AI vision, helping establish AI as a core enabler across the global business primarily through internal and enterprise applications. In this role, Mirza will lead the integration of advanced analytics, machine learning and intelligent automation across Mirion operations and processes. This will include identifying and prioritizing high-impact use cases; optimizing manufacturing and supply chain performance; and implementing governance frameworks for ethical, secure, transparent, and compliant AI use – particularly important in highly regulated environments. Mirza previously served as Senior Director of Data, AI/Machine Learning, and Research and Development at 7-Eleven, where he led enterprise data and AI strategies in support of multi-million-dollar incremental sales. He holds over 130 patents, earned a Master of Science in Computer Science and a Bachelor of Science in Chemical and Biomolecular Engineering from the Georgia Institute of Technology.공시 • Jan 22Mirion Technologies, Inc. to Report Q4, 2025 Results on Feb 10, 2026Mirion Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026공시 • Dec 02Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The transaction will also be financed through a $350 million public offering and $250 Million convertible notes due 2031.The transaction is valued at an approximate multiple of 18 times the estimated 2026 Adjusted EBITDA. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC on December 1, 2025.공시 • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.공시 • Oct 16Mirion Technologies, Inc. to Report Q3, 2025 Results on Oct 28, 2025Mirion Technologies, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025공시 • Sep 26Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 17,309,846 Price\Range: $21.35공시 • Sep 25Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million.Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 14,227,642 Price\Range: $24.6공시 • Sep 24Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC.공시 • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.공시 • Jul 22Mirion Technologies Unveils the Vital Platform, a Digital Ecosystem Powering Integrated Operations for Nuclear Energy and BeyondMirion Technologies announced the launch of the Vital Platform. This software offers a single, unified system for accessing data across nuclear power sites to work more efficiently, enhance worker safety, and solve operational challenges faster. The launch includes the platform's first application, Vital Supervision, designed to enhance radiological instrument data visibility, improve response times, and simplify oversight across critical radiological systems. The Vital Platform was developed to meet nuclear industry demands for a more connected and efficient way to manage radiological instrument data. Rather than relying on fragmented systems or manual processes, Vital enables teams to work within one streamlined environment prioritizing speed, security, and long-term adaptability. Key benefits to customers include: Data Integration and Real Time Monitoring: Real-time tracking across systems enables faster, proactive responses. Regulatory Compliance and Reporting: Automated, standardized reporting simplifies regulatory alignment. Operational Efficiency and Cost Reduction: Streamlined workflows cut time, reduce errors, and lower costs. Security and Risk Mitigation: Access controls and cybersecurity safeguard sensitive data. Facilitating Advanced Analytics: Detailed data helps predict risks and improve decision-making. Scalability and Future Proofing: Modular design supports growth and adapts to change. Supervision: The First Vital Platform Application. Vital Supervision is the first in a series of applications to be built on the Vital Platform, with the aim to unify the capabilities of siloed, standalone software into one platform. This application simplifies the collection and analysis of data from a wide variety of radiological instruments. Real-time, at-a-glance access to alarms, measurement data and instrument health significantly enhances the monitoring and management of critical equipment. The Vital Platform and Vital Supervision application will be showcased at two key upcoming industry events. A webbinar presentation facilitated through Nuclear Engineering International (July 23) and Mirion's annual users' conference Mirion Connect (July 28-August 1) will offer opportunities to explore platform capabilities in depth.공시 • Jul 17Mirion Technologies, Inc. to Report Q2, 2025 Results on Jul 31, 2025Mirion Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025공시 • Jun 30+ 4 more updatesMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexBoard Change • Jun 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jun 20Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio At Snmmi Annual MeetingMirion announced that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies. Deuting at the 2025 SNMMI Annual Meeting: Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent Phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose®?VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company; The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio: ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™? QMS, NMIS™?, and BioRx™? will be available throughout the SNMMI Annual Meeting. Apex-Guard™? Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo®? Probe and RDS-Med™? Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™? Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™? Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. Commitment to Patient Care and Safety: Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging.이익 및 매출 성장 예측BMV:MIR * - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,307N/A224293312/31/20271,22582200222812/31/20261,1384516020883/31/20269812589127N/A12/31/202592529107143N/A9/30/20259022793131N/A6/30/20258861084126N/A3/31/2025870-1084129N/A12/31/2024861-365099N/A9/30/2024837-6656105N/A6/30/2024821-6567112N/A3/31/2024811-8162104N/A12/31/2023801-975895N/A9/30/2023788-2351753N/A6/30/2023758-270-1916N/A3/31/2023737-301-825N/A12/31/2022718-277539N/A9/30/2022678-205-274N/A6/30/2022661-204-429N/A3/31/2022665-199335N/A12/31/2021668-222335N/A9/30/2021641-1654471N/A6/30/2021612-1583054N/A3/31/2021573-1552853N/A6/30/2020478-1192040N/A6/30/2019440-122N/A15N/A6/30/2018444-104N/A16N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MIR * 의 연간 예상 수익 증가율(64.4%)이 saving rate(9%)보다 높습니다.수익 vs 시장: MIR * 의 연간 수익(64.4%)이 MX 시장(8.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: MIR * 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: MIR * 의 수익(연간 10.4%)이 MX 시장(연간 6.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: MIR * 의 수익(연간 10.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MIR *의 자본 수익률은 3년 후 9.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YTech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/22 21:15종가2026/06/03 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Mirion Technologies, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Quinn FredricksonBairdRobert MasonBairdYuan ZhiB. Riley Securities, Inc.8명의 분석가 더 보기
공시 • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.
공시 • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.
공시 • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.
New Risk • Jun 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Shares are highly illiquid. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Significant insider selling over the past 3 months (Mex$2.8m sold).
Board Change • Jun 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.
공시 • Apr 16Mirion Technologies, Inc. to Report Q1, 2026 Results on Apr 28, 2026Mirion Technologies, Inc. announced that they will report Q1, 2026 results After-Market on Apr 28, 2026
공시 • Apr 02Mirion Technologies, Inc., Annual General Meeting, May 13, 2026Mirion Technologies, Inc., Annual General Meeting, May 13, 2026.
공시 • Feb 11+ 1 more updateMirion Technologies, Inc. Announces Management AppointmentsMirion Technologies, Inc. announced three new leadership appointments supporting the company’s continued focus on safety, innovation, operational excellence and long-term growth. Mirion has promoted Tighe Smith to the newly created role of Chief Nuclear Officer. Reporting to Thomas Logan, Mirion Chairman and Chief Executive Officer, Smith will lead the company’s global nuclear strategy across the existing operating fleet as well as the rapidly expanding advanced and small modular reactor (SMR) markets. Smith brings more than 20 years of experience spanning nuclear engineering, digital safety systems, international commercial leadership, and industry policy engagement. Smith most recently held the Chief Nuclear Officer role at Paragon Energy Solutions, now part of Mirion, and will retain these duties in addition to his expanded role. He is also an active contributor to the broader nuclear community, serving as a Trustee of the American Nuclear Society and as Convenor of IEC SC45A Working Group 9, helping advance international standards for nuclear instrumentation and control. He holds a Bachelor of Science in Nuclear Engineering and an MBA from the University of Tennessee, Knoxville. In addition to Nuclear Power, Nuclear Medicine serves as a robust, continually evolving market for Mirion. To further support Mirion’s strategic growth in this key market, Shelia Webb becomes President of Nuclear Medicine. In this role, Webb will lead the overall Nuclear Medicine business unit, focusing on strategic development and furthering the integration of the ec Software and Capintec brands to support advanced cancer care. Webb most recently served as Mirion Chief Digital Officer, playing a pivotal role in building a digital ecosystem that connects operating groups and enhances Mirion capabilities, efficiency and value. Following Mirion’s acquisition of ecSoftware in 2023, Webb assumed responsibility of business unit leader for ec Software and has been instrumental in integrating the company into the broader Capintec portfolio. Mirion also announced the appointment of Shahmeer Mirza as the company’s inaugural Chief Artificial Intelligence & Digital Officer, a new role intended to accelerate Mirion’s commitment to operational excellence and scalable growth through responsible, transformative AI strategies. In this role, Mirza assumes responsibility for Mirion’s Digital strategy as Webb transitions to the role of President, Nuclear Medicine. As Chief AI and Digital Officer, Mirza will lead the continuation of Mirion’s digital transformation roadmap leveraging technologies like AI to innovate, improve processes, and create new revenue streams. Reporting directly to Logan, Mirza will shape and execute the company’s AI vision, helping establish AI as a core enabler across the global business primarily through internal and enterprise applications. In this role, Mirza will lead the integration of advanced analytics, machine learning and intelligent automation across Mirion operations and processes. This will include identifying and prioritizing high-impact use cases; optimizing manufacturing and supply chain performance; and implementing governance frameworks for ethical, secure, transparent, and compliant AI use – particularly important in highly regulated environments. Mirza previously served as Senior Director of Data, AI/Machine Learning, and Research and Development at 7-Eleven, where he led enterprise data and AI strategies in support of multi-million-dollar incremental sales. He holds over 130 patents, earned a Master of Science in Computer Science and a Bachelor of Science in Chemical and Biomolecular Engineering from the Georgia Institute of Technology.
공시 • Jan 22Mirion Technologies, Inc. to Report Q4, 2025 Results on Feb 10, 2026Mirion Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026
공시 • Dec 02Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The transaction will also be financed through a $350 million public offering and $250 Million convertible notes due 2031.The transaction is valued at an approximate multiple of 18 times the estimated 2026 Adjusted EBITDA. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC on December 1, 2025.
공시 • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.
공시 • Oct 16Mirion Technologies, Inc. to Report Q3, 2025 Results on Oct 28, 2025Mirion Technologies, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025
공시 • Sep 26Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 17,309,846 Price\Range: $21.35
공시 • Sep 25Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million.Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 14,227,642 Price\Range: $24.6
공시 • Sep 24Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC.
공시 • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.
공시 • Jul 22Mirion Technologies Unveils the Vital Platform, a Digital Ecosystem Powering Integrated Operations for Nuclear Energy and BeyondMirion Technologies announced the launch of the Vital Platform. This software offers a single, unified system for accessing data across nuclear power sites to work more efficiently, enhance worker safety, and solve operational challenges faster. The launch includes the platform's first application, Vital Supervision, designed to enhance radiological instrument data visibility, improve response times, and simplify oversight across critical radiological systems. The Vital Platform was developed to meet nuclear industry demands for a more connected and efficient way to manage radiological instrument data. Rather than relying on fragmented systems or manual processes, Vital enables teams to work within one streamlined environment prioritizing speed, security, and long-term adaptability. Key benefits to customers include: Data Integration and Real Time Monitoring: Real-time tracking across systems enables faster, proactive responses. Regulatory Compliance and Reporting: Automated, standardized reporting simplifies regulatory alignment. Operational Efficiency and Cost Reduction: Streamlined workflows cut time, reduce errors, and lower costs. Security and Risk Mitigation: Access controls and cybersecurity safeguard sensitive data. Facilitating Advanced Analytics: Detailed data helps predict risks and improve decision-making. Scalability and Future Proofing: Modular design supports growth and adapts to change. Supervision: The First Vital Platform Application. Vital Supervision is the first in a series of applications to be built on the Vital Platform, with the aim to unify the capabilities of siloed, standalone software into one platform. This application simplifies the collection and analysis of data from a wide variety of radiological instruments. Real-time, at-a-glance access to alarms, measurement data and instrument health significantly enhances the monitoring and management of critical equipment. The Vital Platform and Vital Supervision application will be showcased at two key upcoming industry events. A webbinar presentation facilitated through Nuclear Engineering International (July 23) and Mirion's annual users' conference Mirion Connect (July 28-August 1) will offer opportunities to explore platform capabilities in depth.
공시 • Jul 17Mirion Technologies, Inc. to Report Q2, 2025 Results on Jul 31, 2025Mirion Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025
공시 • Jun 30+ 4 more updatesMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value Index
Board Change • Jun 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jun 20Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio At Snmmi Annual MeetingMirion announced that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies. Deuting at the 2025 SNMMI Annual Meeting: Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent Phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose®?VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company; The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio: ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™? QMS, NMIS™?, and BioRx™? will be available throughout the SNMMI Annual Meeting. Apex-Guard™? Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo®? Probe and RDS-Med™? Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™? Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™? Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. Commitment to Patient Care and Safety: Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging.